1. Home
  2. MURA vs AIRE Comparison

MURA vs AIRE Comparison

Compare MURA & AIRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MURA
  • AIRE
  • Stock Information
  • Founded
  • MURA 2013
  • AIRE 2021
  • Country
  • MURA Ireland
  • AIRE United States
  • Employees
  • MURA N/A
  • AIRE N/A
  • Industry
  • MURA
  • AIRE
  • Sector
  • MURA
  • AIRE
  • Exchange
  • MURA Nasdaq
  • AIRE Nasdaq
  • Market Cap
  • MURA 35.7M
  • AIRE 39.4M
  • IPO Year
  • MURA N/A
  • AIRE N/A
  • Fundamental
  • Price
  • MURA $2.08
  • AIRE $0.67
  • Analyst Decision
  • MURA Strong Buy
  • AIRE Hold
  • Analyst Count
  • MURA 3
  • AIRE 1
  • Target Price
  • MURA $12.00
  • AIRE N/A
  • AVG Volume (30 Days)
  • MURA 497.8K
  • AIRE 12.0M
  • Earning Date
  • MURA 08-04-2025
  • AIRE 08-14-2025
  • Dividend Yield
  • MURA N/A
  • AIRE N/A
  • EPS Growth
  • MURA N/A
  • AIRE N/A
  • EPS
  • MURA N/A
  • AIRE N/A
  • Revenue
  • MURA N/A
  • AIRE $3,043,657.00
  • Revenue This Year
  • MURA N/A
  • AIRE $354.12
  • Revenue Next Year
  • MURA N/A
  • AIRE $62.13
  • P/E Ratio
  • MURA N/A
  • AIRE N/A
  • Revenue Growth
  • MURA N/A
  • AIRE 2973.28
  • 52 Week Low
  • MURA $0.95
  • AIRE $0.14
  • 52 Week High
  • MURA $4.74
  • AIRE $4.49
  • Technical
  • Relative Strength Index (RSI)
  • MURA 52.06
  • AIRE 74.15
  • Support Level
  • MURA $2.05
  • AIRE $0.37
  • Resistance Level
  • MURA $2.09
  • AIRE $0.58
  • Average True Range (ATR)
  • MURA 0.01
  • AIRE 0.07
  • MACD
  • MURA 0.02
  • AIRE 0.03
  • Stochastic Oscillator
  • MURA 62.50
  • AIRE 75.78

About MURA Mural Oncology plc

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

About AIRE reAlpha Tech Corp.

ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are; Platform Services and the Rental business segment.

Share on Social Networks: